At JPM26, Gilead showcased strong momentum as Yeztugo’s impressive sales and positive HIV treatment outlook boosted investor sentiment, capturing the optimistic mood at the biotech conference.
Browsing: HIV
At JPM26, Gilead showcased strong momentum as Yeztugo’s impressive sales and positive HIV treatment outlook boosted investor sentiment, capturing the optimistic mood at the biotech conference.